마케팅커뮤니케이션2022-07-22Hit 3581
■ Selected as the
developer of AI software solutions for rare diseases through consortium
participation, leveraging rich experience in producing genetic data and
expertise in genome analysis.
■ Constructing an
integrated software solution for reducing diagnostic wandering period with the
Korea Centers for Disease Control and Prevention and Seoul National University
Hospital from 2021.
■ Strengthening Theragen
Bio's ‘social responsibility’ and “becoming a company that develops technology
for the benefit of the world”
Theragen Bio, a global genome analysis service and AI-based drug development company (CEO: Samuel Hwang), has been selected as a developer for the "Integrated AI Software Solution for Multi-Omics Analysis of Pediatric Rare Diseases" project in collaboration with Seoul National University Hospital and Kakao Healthcare Consortium. The project, which is hosted by the Ministry of Science and ICT's evaluation agency, will receive a total research budget of KRW 9.7 billion from this year to 2024. The aim is to develop cloud-based software solutions including AI models for the diagnosis and prognosis management of nine rare disease groups in pediatric patients. The project involves the participation of four companies, including Theragen Bio and Kakao Healthcare, and five hospitals, including Seoul National University Hospital, Seoul St. Mary's Hospital, Samsung Seoul Hospital, Pusan National University Hospital, and Kyungpook National University Hospital.
In this project, Theragen Bio will ▲propose solutions for treating rare diseases and ▲produce sequencing data for verifying diagnostic software. To achieve this, they will analyze around 33 million biomedical literature using AI technology, perform text mining for pediatric rare diseases, and develop algorithms for proposing diagnostic and treatment solutions. Additionally, they plan to build whole genome data for 900 patients for AI software verification for pediatric rare diseases at a total of 13 nationwide clinical validation network hospitals, including Chungbuk National University Hospital, Inha University Hospital, Chungnam National University Hospital, Boramae Medical Center, Jeju National University Hospital, Ajou University Hospital, and St. Vincent's Hospital.
The CEO of Theragen Bio, Hwang Tae-soon, has stated that the reason his company was selected for the SW (software) project is due to their experience in producing 25,000 genomic data as a consortium member for both the 1st and 2nd Bio Big Data preliminary projects supervised by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare. He further added that he is pleased with the company's extensive genomic analysis experience, which can contribute to the accurate and rapid diagnosis of pediatric rare diseases and enhance their social responsibility.
Theragen Bio is building a platform for rare disease researchers to share their experiences in the 'Lee Kun-hee Foundation Project', which has been implemented since April 2021, with 81 base hospitals in each region of Korea and Seoul National University Hospital, a central diagnostic institution based on its experience in establishing an international rare disease information exchange platform with the Korea Centers for Disease Control and Prevention and Seoul National University Hospital. The number of patients (including family members) suffering from rare diseases in Korea is close to 800,000, and their clinical manifestations are diverse, making it difficult for even experienced specialists to prescribe the right treatment in a timely manner.